Tesamorelin Growth Hormone–Releasing Hormone Analogue Overview

Tesamorelin is a synthetic, research-grade growth hormone–releasing hormone (GHRH) analogue consisting of the full 44‐amino acid human GHRH sequence with an added trans‐3‐hexenoic acid group at the N‐terminus to enhance stability and plasma half‐life. It is widely used to model GH axis activation, visceral fat reduction, and neuro‐metabolic effects in both preclinical and clinical research settings.

Molecular Mechanistic Profile

• Mechanistically, Tesamorelin:

  Binds to GHRH receptors on pituitary somatotroph cells, activating cAMP–PKA signaling and stimulating endogenous GH secretion and subsequent IGF‐1 production.

• Preserves physiologic pulsatility of GH release, unlike direct GH administration, thereby leveraging normal hypothalamic–pituitary feedback mechanisms.

• Demonstrates increased resistance to enzymatic degradation in plasma compared with native GHRH due to its trans‐3‐hexenoic N‐terminal group, resulting in a longer half‐life and more sustained GH axis activation.

These properties allow Tesamorelin to serve as a model for chronic GH/IGF‐1 modulation in metabolic and neurologic research.

Integrated Research Applications

• Tesamorelin is employed across several intersecting domains:

• HIV‐associated lipodystrophy and visceral adiposity: FDA‐approved in 2010 for treatment of HIV‐associated lipodystrophy, Tesamorelin has been shown to reduce visceral adipose tissue by nearly 20% in this population and improve lipid profiles (triglycerides, total cholesterol, non‐HDL‐C).

• Cardiometabolic research: Used to investigate how GH‐mediated visceral fat reduction and lipid changes translate into cardiovascular risk modification.

• Neurocognitive and peripheral nerve studies: Under investigation for slowing progression of mild cognitive impairment (MCI) and enhancing peripheral nerve regeneration after injury.

• GH axis synergy: Combined with Ipamorelin or CJC‐1295 (no DAC) in multi‐peptide blends to explore additive or synergistic GH secretagogue effects via simultaneous GHRH and ghrelin‐receptor pathways.

These research directions utilize Tesamorelin’s regulatory rather than replacement‐style action on the GH axis.

Analytical Validation, Formulation, and Storage

Research Tesamorelin products (5 mg or 10 mg vials) are supplied as lyophilized powder intended for reconstitution immediately prior to use. Typical specifications include:

• Purity: ≥98–99% by HPLC.

• Identity: Confirmed via mass spectrometry and peptide mapping consistent with the 44‐amino acid GHRH analogue and the C221H366N72O67S formula.

• Appearance: White to off‐white amorphous or lyophilized powder.

  Storage and product care (matching your format):

• Store in a cool, dry place away from light while lyophilized.

• After constitution, refrigerate the solution. For longer‐term storage, freezing at approximately −20 °C is recommended to maintain integrity.

NextGenPeps supplies tesamorelin as a high-purity research peptide intended strictly for laboratory experimentation. This compound is not approved for human consumption or clinical use outside authorized research protocols.